IgG anti-cardiolipin antibodies-markers of inflammation in diabetic patients with ischemic stroke.
Some researchers investigated the role of anticardiolipin antibodies in the pathogenesis of the ischemic stroke. The objective of the study was to evaluate the relationship between the prevalence of the IgG anti-cardiolipin antibodies (IgG aCL) and ischemic stroke in patients with diabetes mellitus. IgG aCL were prospectively investigated in 87 diabetic patients with ischemic stroke (mean age 78.5 years) and in 68 diabetic patients without ischemic stroke (mean age 72.8 years). IgG aCL were determined by ELISA. Twenty-three out of 87 diabetic patients without ischemic stroke had IgG aCL and 25 out of 68 diabetic patients without stroke had IgG aCL. The IgG aCL titer did not differ significantly between patients with ischemic stroke and those without stroke (p>0.05). Our data showed that IgG aCL are not a risk factor for ischemic stroke in diabetic patients. Both patients with diabetes and those with diabetes and ischemic stroke had serum IgG aCL. IgG aCL indicate inflammatory conditions in these pathologies.